GKOS earnings analysis
What we found in GKOS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Glaukos Corporation (GKOS) reported a strong Q1 2026 performance with revenues of $150.6 million, surpassing expectations by 9.9%, and a narrower loss per share of -$0.18, better than the estimated -$0.28. Management raised its revenue outlook for 2026 significantly to a range of $620 million to $635 million, implying robust growth momentum, chiefly from its glaucoma segment and new product launches.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Strong Revenue Growth
- Revenue increased from $106.7 million in Q1 2025 to $150.6 million, a 41.1% jump year-over-year.
- Improved Earnings Performance
- EPS improved from -$0.34 in Q1 2025 to -$0.18 in Q1 2026, reflecting a better cost structure.
- Increased Gross Margin
- Gross margin rose to 78% in Q1 2026 from 77% a year earlier, driven by efficient production.
- Raised Full-Year Revenue Guidance
- Revised revenue guidance for 2026 to $620M-$635M, up from $600M-$620M.
- Key Product Launch Contributions
- International glaucoma product sales saw a growth of 23%, significantly impacting overall revenue.
- Controlled Launch of Epioxa
- Introduced Epioxa for keratoconus, anticipated to enhance future revenue streams.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Uncertain Reimbursement Environment
- Changes in reimbursement policies may disrupt adoption rates of new products like iDose TR and Epioxa.
- Increasing Operating Expenses
- Operating expenses rose to $137.1 million, up from $103 million year-over-year, impacting net losses.
- Supply Chain Risks
- Macroeconomic factors and geopolitical tensions could adversely affect logistics and raw material costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
- Gross margin
- 78%
- Segment
- U.S. Glaucoma Products
- Segment
- Corneal Health Products
What they said about what is next.
Management anticipates strong sales growth driven by glaucoma product demand.
The filing reads better than the one before it.
What came before.
- 10-Q · May 1, 2025
- Glaukos reported Q1 2025 revenue of $106,664,000 (up from $85,622,000 in Q1 2024) and GAAP net loss per share narrowed to $(0.32) from $(0.82). Gross margin expanded to 77.2% and loss from operations improved to…
- 10-Q · November 5, 2024
- Q3 2024 results show solid top-line growth and margin stability but the company remains unprofitable and cash flow negative. Net sales rose to $96.67M while gross margin held at ~76.7%; diluted loss per share improved…
- 10-Q · August 2, 2023
- Q2 2023 results showed top-line growth with improving operating performance but continued net losses and negative free cash flow. Net sales rose to $80,399 (Q2 2023) from $72,685 (Q2 2022) and operating loss narrowed to…
- 10-K · February 24, 2023
- Glaukos positions itself as a diversified ophthalmic medical technology and pharmaceutical company with three principal end markets: glaucoma, corneal disorders and retinal diseases. The 2022 filing highlights strong…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GKOS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever